(LENZ) LENZ Therapeutics - Ratings and Ratios
Presbyopia, Accommodative, Therapeutics
| Risk via 10d forecast | |
|---|---|
| Volatility | 90.7% |
| Value at Risk 5%th | 127% |
| Reward | |
|---|---|
| Sharpe Ratio | -0.14 |
| Alpha Jensen | -44.62 |
| Character | |
|---|---|
| Hurst Exponent | 0.391 |
| Beta | 1.544 |
| Drawdowns 3y | |
|---|---|
| Max DD | 56.23% |
| Mean DD | 22.87% |
Description: LENZ LENZ Therapeutics August 27, 2025
LENZ Therapeutics Inc, a biotechnology company listed on NASDAQ under the ticker symbol LENZ, operates in the United States. The companys stock is classified as common stock within the biotechnology sub-industry according to the GICS classification.
The quarterly tax provision data suggests that the company is navigating complex financial and operational challenges, potentially related to its research and development activities, a common characteristic of biotech firms. Biotech companies often report significant losses due to high R&D expenses, which can lead to negative earnings and, consequently, a P/E ratio of 0.00, as seen in LENZs financials.
With a market capitalization of $1036.21M USD, LENZ Therapeutics has a considerable presence in the market. The absence of a Beta value indicates that the companys stock volatility relative to the overall market is not readily available or calculable, possibly due to the stocks relatively short trading history or insufficient data. The negative Return on Equity (RoE) of -25.63% highlights the companys current unprofitability, a common trait among biotech firms that are investing heavily in drug development.
Key economic drivers for LENZ include the success of its drug pipeline, regulatory approvals, and the ability to bring new therapies to market. Critical KPIs to watch would include the progress of clinical trials, the companys cash burn rate, and the estimated time to profitability. The stocks price action, with a current price of $39.68 and a 52-week range of $18.32 to $40.91, indicates significant volatility and potential investor interest in the companys prospects.
The average trading volume of 611,142 shares suggests a relatively liquid stock, which is important for investors looking to enter or exit positions without significantly impacting the stock price. The short-term and long-term moving averages (SMA20, SMA50, SMA200) indicate a positive trend, with the stock price above these averages, suggesting a potential uptrend.
LENZ Stock Overview
| Market Cap in USD | 719m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2021-06-25 |
| Return 12m vs S&P 500 | -36.0% |
| Analyst Rating | 4.63 of 5 |
LENZ Dividends
Currently no dividends paidLENZ Growth Ratios
| CAGR | 3.82% |
| CAGR/Max DD Calmar Ratio | 0.07 |
| CAGR/Mean DD Pain Ratio | 0.17 |
| Current Volume | 1501.8k |
| Average Volume | 1169.8k |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-58.9m TTM) > 0 and > 6% of Revenue (6% = 1.05m TTM) |
| FCFTA -0.22 (>2.0%) and ΔFCFTA 10.06pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.21 (>3.0%) and CFO -45.2m > Net Income -58.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 12.69 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (28.5m) change vs 12m ago 5.04% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 8.08% (prev 0.0%; Δ 8.08pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.23 (EBITDA TTM -67.8m / Interest Expense TTM 9.37m) >= 6 (WARN >= 3) |
Altman Z'' -10.49
| (A) 0.90 = (Total Current Assets 207.0m - Total Current Liabilities 16.3m) / Total Assets 210.7m |
| (B) -0.91 = Retained Earnings (Balance) -191.2m / Total Assets 210.7m |
| (C) -0.23 = EBIT TTM -49.0m / Avg Total Assets 217.4m |
| (D) -11.39 = Book Value of Equity -191.0m / Total Liabilities 16.8m |
| Total Rating: -10.49 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 38.45
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -8.93% = -4.46 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.00 = 2.50 |
| 5. Debt/Ebitda 0.37 = 2.40 |
| 6. ROIC - WACC (= -36.21)% = -12.50 |
| 7. RoE -29.58% = -2.50 |
| 8. Rev. Trend 65.32% = 4.90 |
| 9. EPS Trend 62.47% = 3.12 |
What is the price of LENZ shares?
Over the past week, the price has changed by +15.37%, over one month by -31.39%, over three months by -32.70% and over the past year by -27.11%.
Is LENZ Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LENZ is around 22.46 USD . This means that LENZ is currently overvalued and has a potential downside of -15.21%.
Is LENZ a buy, sell or hold?
- Strong Buy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the LENZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 53.5 | 102% |
| Analysts Target Price | 53.5 | 102% |
| ValueRay Target Price | 25.8 | -2.7% |
LENZ Fundamental Data Overview November 11, 2025
P/S = 41.0703
P/B = 6.6784
Beta = None
Revenue TTM = 17.6m USD
EBIT TTM = -49.0m USD
EBITDA TTM = -67.8m USD
Long Term Debt = 1.38m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 567.0k USD (from shortTermDebt, last fiscal year)
Debt = 461.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -24.9m USD (from netDebt column, last quarter)
Enterprise Value = 517.0m USD (718.7m + Debt 461.0k - CCE 202.2m)
Interest Coverage Ratio = -5.23 (Ebit TTM -49.0m / Interest Expense TTM 9.37m)
FCF Yield = -8.93% (FCF TTM -46.2m / Enterprise Value 517.0m)
FCF Margin = -262.8% (FCF TTM -46.2m / Revenue TTM 17.6m)
Net Margin = -335.2% (Net Income TTM -58.9m / Revenue TTM 17.6m)
Gross Margin = 99.50% ((Revenue TTM 17.6m - Cost of Revenue TTM 88.0k) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 99.62%)
Tobins Q-Ratio = 2.45 (Enterprise Value 517.0m / Total Assets 210.7m)
Interest Expense / Debt = 4.34% (Interest Expense 20.0k / Debt 461.0k)
Taxrate = -0.00% (negative due to tax credits) (1000 / -49.8m)
NOPAT = -49.0m (EBIT -49.0m * (1 - -0.00%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 12.69 (Total Current Assets 207.0m / Total Current Liabilities 16.3m)
Debt / Equity = 0.00 (Debt 461.0k / totalStockholderEquity, last quarter 193.9m)
Debt / EBITDA = 0.37 (negative EBITDA) (Net Debt -24.9m / EBITDA -67.8m)
Debt / FCF = 0.54 (negative FCF - burning cash) (Net Debt -24.9m / FCF TTM -46.2m)
Total Stockholder Equity = 199.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.95% (Net Income -58.9m / Total Assets 210.7m)
RoE = -29.58% (Net Income TTM -58.9m / Total Stockholder Equity 199.1m)
RoCE = -24.45% (EBIT -49.0m / Capital Employed (Equity 199.1m + L.T.Debt 1.38m))
RoIC = -24.41% (negative operating profit) (NOPAT -49.0m / Invested Capital 200.8m)
WACC = 11.81% (E(718.7m)/V(719.2m) * Re(11.81%) + D(461.0k)/V(719.2m) * Rd(4.34%) * (1-Tc(-0.00)))
Discount Rate = 11.81% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 85.58%
Fair Price DCF = unknown (Cash Flow -46.2m)
EPS Correlation: 62.47 | EPS CAGR: 20.28% | SUE: 0.10 | # QB: 0
Revenue Correlation: 65.32 | Revenue CAGR: 139.2% | SUE: 4.0 | # QB: 2
Additional Sources for LENZ Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle